anti-CD19 CAR-NK-cell therapy (Zhejiang University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD19 CAR-NK-cell therapy (Zhejiang University)
Drug Alias NameCAR-NK-019CB-CAR-NK-019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunostimulantsNatural killer cells stimulantsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicLymphoma, Mantle-Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicLymphoma, Mantle-Cell +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A